HOME >> MEDICINE >> NEWS
Imatinib (Gleevec) has activity in AIDS-related Kaposi's sarcoma

Alexandria, VA--A new clinical study has shown that imatinib mesylate (Gleevec) has activity in AIDS-related Kaposi's sarcoma (KS). Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients. The study will be published November 30 in the Journal of Clinical Oncology (JCO).

"Imatinib is a targeted therapy originally shown to be effective in treating chronic myelogenous leukemia and gastrointestinal stromal tumors. This study and others are showing that the drug is also active in other cancers that express some of the same proteins," said Henry B. Koon, MD, Instructor of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, and lead author of the study. "Studies like this one represent an exciting time in oncology, when our understanding of the development of diseases like KS coincide with the availability of effective treatments. Further research on imatinib in KS patients will be needed to determine appropriate dosing schedules."

Kaposi's sarcoma is an AIDS-defining illness characterized by soft purplish lesions on the skin, mucous membranes, and internal organs. Although the incidence of KS has declined dramatically in the developed world since the advent of highly active antiretroviral therapies (HAART), it remains a significant cause of morbidity and mortality for AIDS patients in the United States and a major cause of mortality in the third world, given the limited number of effective treatments for KS.

Researchers examined the response of Kaposi's sarcoma to imatinib, a drug known to inhibit the PDGF-R and/or c-kit pathways that are responsible for the growth of other cancers, such as chronic myelogenous leukemia, gastrointestinal stromal tumors (GIST), and bone sarcomas of the head and neck. Given that PDGF-R and c-kit also play a role in the development of KS, researchers theorized that imatinib may be an effective strategy
'"/>

Contact: Danielle Potuto
potutod@asco.org
703-519-1422
American Society of Clinical Oncology
30-Nov-2004


Page: 1 2

Related medicine news :

1. Imatinib shows early promise against Ewings sarcoma
2. Brain activity prior to treatment flags vulnerability to antidepressant side effects
3. Physical activity linked to protection from Parkinsons disease
4. Brain activity of men and women during hostile or impulsive acts differs less on nicotine
5. Abnormal brain activity during the observation of others actions
6. Increased physical activity not linked to ALS risk
7. Maintaining physical activity linked to less cognitive decline in older men
8. Daily social/physical activity improves sleep and cognition in the elderly
9. Celecoxib shows surprising activity against estrogen receptors
10. Jefferson scientists find way to see breast cancer activity from outside the body
11. Brain activity reflects complexity of responses to other-race faces

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Imatinib Gleevec has activity AIDS related Kaposi sarcoma

(Date:8/28/2015)... ... , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn recently ... for, they are unable to pass the initial drug test and therefore unable to ... order to be able to hire long-term, skilled talent. (1) Will Wesch, Director of ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is ... with their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known ... stroke. They believe that together, a difference can be made. Walkers can participate in ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor ... Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an official ... , “With the help of the medical community and the University of Illinois at ...
(Date:8/28/2015)... ... 2015 , ... Saint Petersburg, FL —Pocket Protein™, a protein ... sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that never ... Choice Awards. , Five consumer packaged goods (CPG) products were selected by the ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... specialist, Dr. James Strawbridge, gives a new approach on solutions in his new ... with the employer and employees getting together for meaningful group meetings. "This would ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
(Date:8/28/2015)... ANGELES , FARUM, Denmark and ... On July 31, 2015 the US Food and ... the treatment of Major Depressive Disorder in adult patients who ... in the current episode. TMS is a non-invasive technique for ... in patients suffering from Major Depressive Disorder. The procedure has ...
(Date:8/28/2015)... India , August 28, 2015 ... Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ... , Asia-Pacific , and Rest of the ... MarketsandMarkets, The global market for Eubiotics was valued at USD ... 7.05 Billion by 2020, at a CAGR of 7.4% from ...
(Date:8/28/2015)... August 28, 2015 The global ... USD 49.12 billion by 2020, growing at a CAGR ... new report by Grand View Research, Inc. Monitoring services ... 49.7% from 2014 to 2020.      (Logo: ... along with rising incidences of chronic diseases such as ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5
Cached News: